Biodesix (BDSX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
Annual meeting scheduled for May 19, 2026, to be held virtually for all stockholders of record as of March 23, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of two Class III directors to serve until the 2029 annual meeting: Jean Franchi and Hany Massarany.
Advisory vote to approve compensation of named executive officers.
Advisory vote on the frequency of executive compensation votes, with the board recommending every 1 year.
Ratification of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.
Consideration of other business properly brought before the meeting.
Board of directors and corporate governance
Board recommends voting for all director nominees and all proposals.
Latest events from Biodesix
- Sales and clinical momentum support growth, with profitability and pipeline progress in focus.BDSX
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 34% to $26.9M, gross margin at 82%, and net loss improved by 37%.BDSX
Q2 2026 - Strong growth, digital expansion, and clinical innovation set the stage for a transformative 2025.BDSX
45th Annual William Blair Growth Stock Conference - Revenue and clinical adoption surge as targeted lung nodule diagnostics drive growth.BDSX
46th Annual William Blair Growth Stock Conference - Registering 375,000 shares for resale by a lender, with proceeds from warrant exercises for working capital.BDSX
Registration filing - Rapidly growing lung diagnostics innovator with strong financials and broad clinical impact.BDSX
Corporate presentation - Q1 2026 revenue rose 42% to $25.6M, with improved margins and raised full-year guidance.BDSX
Q1 2026 - Annual meeting to vote on directors, executive pay, auditor, and governance best practices.BDSX
Proxy filing - Q1 2025 revenue up 21%, net loss improved 18%, and 2025 guidance set at $80–85 million.BDSX
Q1 2025